SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

Search

BioMerieux

Open

BrancheGesundheitswesen

117.8 -0.93

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

117.8

Max

119.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

215M

Verkäufe

-1.1B

785M

KGV

Branchendurchschnitt

31.374

63.778

Dividendenrendite

0.77

Gewinnspanne

11.32

Angestellte

14,147

EBITDA

-247M

161M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+15.58% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.77%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

14B

Vorheriger Eröffnungskurs

118.73

Vorheriger Schlusskurs

117.8

Nachrichtenstimmung

By Acuity

19%

81%

36 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

BioMerieux Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3. Apr. 2025, 22:40 UTC

Wichtige Markttreiber

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3. Apr. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3. Apr. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3. Apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3. Apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3. Apr. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 21:43 UTC

Top News
Ergebnisse

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3. Apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3. Apr. 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3. Apr. 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3. Apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3. Apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3. Apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3. Apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3. Apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3. Apr. 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3. Apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3. Apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3. Apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3. Apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

BioMerieux Prognose

Kursziel

By TipRanks

15.58% Vorteil

12-Monats-Prognose

Durchschnitt 133.5 EUR  15.58%

Hoch 140 EUR

Tief 129 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMerieux – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

115.8 / 117.5Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

36 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.